FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves
Executive Summary
The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. Other CDK2 inhibitors have had ocular toxicity issues as well.